The startup has developed a therapeutic platform that utilizes artificial intelligence and big data to create targeted molecules for treating rare cancers. This approach enables physicians to access more effective drugs tailored to individual patient needs, improving treatment outcomes.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current precision medicine approaches for cancer treatment often focus on matching drugs to single mutations, failing to account for the complex interactions of drugs with the thousands of genes defining a patient's unique cancer fingerprint. This oversimplified approach may lead to suboptimal treatment recommendations, especially for rare cancers where effective options are limited. The delay in obtaining comprehensive drug-response profiles further hinders timely intervention.
Solution
SHEPHERD utilizes a therapeutic platform, DELVE, that analyzes a patient's unique cancer fingerprint, considering the impact of drugs on over 20,000 genes to provide true precision medicine. By decoding the complex interactions between drugs and the entire cancer fingerprint, DELVE identifies thousands of match points, leading to personalized drug recommendations. The platform delivers comprehensive reports in a few days, enabling physicians to make informed decisions quickly and improve treatment outcomes for patients with rare cancers.
Target Audience
The primary target audience includes physicians treating patients with rare cancers, as well as patients seeking personalized treatment options when standard therapies have failed.
Features
- Analyzes over 20,000 genes to define a patient's unique cancer fingerprint.
- Decodes the impact of every drug on every gene within the cancer fingerprint.
- Identifies thousands of match points between drugs and a patient's specific cancer profile.
- Delivers comprehensive reports with personalized drug recommendations within days of receiving sequencing data.